

1
2
3
4
5
6
7
8
9

**DEPARTMENT OF HEALTH
MEDICAL QUALITY ASSURANCE
BOARD OF OPTOMETRY**

**MINUTES – DRAFT
TOPICAL OCULAR PHARMACEUTICAL AGENTS COMMITTEE**

February 14, 2012

10 Agenda items are subject to being taken up at anytime during the meeting. Participants in this
11 public meeting should be aware that these proceedings are being recorded and that an audio file
12 of the meeting will be posted to the board's website.
13
14
15

16 **CALL TO ORDER:**

17 Dr. James Watts, Chair, called the meeting to order on Tuesday, February 14, beginning at 9:00
18 a.m. Those present for all or part of the meeting included the following:
19

20 **MEMBERS PRESENT:**

21 James Watts, O.D., Chair
22 Mark Dunbar, O.D.
23 Magdi R.I. Soliman, Ph.D.
24 Lee Duffner, M.D.
25 Emanuel Newmark, M.D.
26

27 **STAFF PRESENT:**

28 Bruce Deterding, Executive Director
29 Sharon Guilford, Program Operations Administrator
30 Jose Montalvan, Regulatory Supervisor/Consultant
31 Sherra Causey, Regulatory Specialist II
32

33 **BOARD COUNSEL:**

34 C. Khai Patterson, Assistant Attorney General
35 Office of Attorney General
36

37 **DISCUSSION OF THE ADDITION OF NATACYN TO THE FORMULARY:**
38

39 **Additional Information from Florida Optometric Association**

40 **Request from Dr. Newmark**

41 **Notice of Addition to the Formulary**

42 **Request of Addition to the Formulary from Florida Optometric Association**
43

44 The members discussed in detail adding Natacyn to the TOPA Formulary for certified
45 optometrist.
46

47 Mr. John Griffin, Esq, representing the Florida Optometric Association (FOA), requested the
48 addition of Natacyn (natamycin ophthalmic suspension) 5% to the TOPA Formulary for certified
49 optometrists. The FOA requested that a new category entitled, "Antifungal Agents", and placing

1 Natacyn in that category. He also provided a copy of the prescribing information and package
2 insert for Natacyn demonstrating that the agent has been approved by the FDA and has been
3 released for sale.

4

5 The board discussed whether the drug should be under antifungal drug or miscellaneous drug.

6

7 The following action was taken:

8

9 **Dr. Dunbar moved to add Natacyn to the TOPA Formulary for certified optometrist under**
10 **miscellaneous drug. The motion was seconded and carried 5/0.**

11

12 **ADJOURNMENT:**

13

14 The meeting adjourned at 10:30 a.m.